C-reactive protein and asymmetric dimethylarginine: markers or mediators in cardiovascular disorders? by Smith, C.L. & Smith, C.L.
  
 
 
 
WestminsterResearch 
http://www.wmin.ac.uk/westminsterresearch 
 
 
C-reactive protein and asymmetric dimethylarginine: markers 
or mediators in cardiovascular disorders? 
 
Caroline L. Smith 
 
School of Biosciences 
 
 
 
 
This is an electronic version of an article published in Current Pharmaceutical 
Design, 13 (16). pp. 1619-1629, 2007. The definitive version is available 
online at: 
 
http://www.bentham.org/cpd/index.htm 
 
 
 
 
The WestminsterResearch online digital archive at the University of Westminster 
aims to make the research output of the University available to a wider audience.  
Copyright and Moral Rights remain with the authors and/or copyright owners. 
Users are permitted to download and/or print one copy for non-commercial private 
study or research.  Further distribution and any use of material from within this 
archive for profit-making enterprises or for commercial gain is strictly forbidden.    
 
 
 
Whilst further distribution of specific materials from within this archive is forbidden, 
you may freely distribute the URL of WestminsterResearch. 
(http://www.wmin.ac.uk/westminsterresearch). 
 
 
In case of abuse or copyright appearing without permission e-mail wattsn@wmin.ac.uk. 
 Current Pharmaceutical Design, 2007, 13, 000-000 1 
 1381-6128/07 $50.00+.00  © 2007 Bentham Science Publishers Ltd. 
C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in 
Cardiovascular Disorders?  
Caroline L. Smith* 
Department of Molecular and Applied Biology, School of Biosciences, University of Westminster, London, UK 
Abstract: C-reactive protein (CRP) has received much attention as a cardiovascular risk factor and has been recommended to be used in 
screening to assist in predicting the occurrence of cardiovascular disorders. There are numerous association studies documenting changes 
in circulating CRP concentrations, there are, however, fewer studies providing evidence that CRP mediates the progression of cardiovas-
cular pathologies. Elucidating the potential mechanisms for CRP has been confounded by recent reports that contaminants of CRP are 
partially responsible for observed effects.  
In this review the use of CRP as a tool to predict cardiovascular disorders will be discussed alongside a more recently described cardio-
vascular risk factor asymmetric dimethylarginine (ADMA). An endogenously occurring nitric oxide synthase inhibitor, ADMA, is 
formed by the action of protein arginine methyltransferases and subsequent proteolysis and it is metabolised in vivo by the dimethylargin-
ine dimethylaminohydrolases (DDAH). The evidence available documenting the effects of CRP and ADMA, the regulatory mechanisms 
and the genetic influences, will be discussed in order to determine whether CRP and ADMA are mediators in the progression of cardio-
vascular disorders or merely useful biomarkers. 
Key Words: C-reactive protein, asymmetric dimethylarginine, nitric oxide, cardiovascular risk factor, atherosclerosis, dimethylarginine di-
methylaminohydrolase, protein arginine methyltransferase. 
INTRODUCTION 
ADMA and CRP as Cardiovascular Risk Factors 
 In 1992 Vallance et al. reported impaired nitric oxide synthesis 
and elevated concentrations of asymmetric dimethylarginine 
(ADMA) in patients with end stage renal failure and suggested that 
ADMA might contribute to the development of hypertension [1]. In 
a study of men in the Kuopio Ischaemic Heart Disease Risk Factor 
Study, ADMA concentrations exceeding 0.69 mol/L in subjects 
with a history of heart disease were associated with a 4-fold risk of 
a coronary event [2] and in the same issue Zoccali et al. reported 
that in patients with end stage renal disease, raised concentrations 
of ADMA independently predicted mortality and cardiovascular 
outcome [3]. Since this time there have been many studies looking 
at the concentrations of ADMA and the correlation with cardiovas-
cular risk, (these are summarised in Table 1 reviewed by [4]). 
 A panopoly of studies have reported increased C-reactive pro-
tein (CRP) concentrations in cardiovascular related disorders and it 
is not the intention of this review to detail all of these, an overview 
is shown in Table 2. C-reactive protein had been characterised as an 
acute phase protein. One of the first reports of CRP as a cardiovas-
cular risk factor came from observations that circulating concentra-
tions of CRP were increased following myocardial infarction [5]. 
This was followed by a study of a cohort of patients with unstable 
angina where higher concentrations of CRP correlated with poor 
outcome [6]. Concentrations of plasma CRP above 3.6 mg/L were 
associated with a 2-fold risk of a coronary event characterised by 
myocardial infarction or sudden coronary death [7]. Higher concen-
trations of CRP in patients with pre-existing atherosclerosis were 
found to correlate with susceptibility to subsequent cardiovascular 
events [8], and, following myocardial infarction, CRP concentra-
tions predicted adverse short term outcomes [9]. The relative risk of 
a coronary event when circulating CRP concentrations exceeded 3 
mg/L was originally determined to be ~2.0 [10] but in a larger study 
this was revised to 1.45 [11].  
 Interest has been shown in the benefits of measuring risk fac-
tors, in addition to age, family history, exercise, smoking history, 
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Table 1. Summary of Cardiovascular Disorders which have Re-
ported Changes in ADMA Levels. Elevated ADMA (0.6-4 
mol/L) Correlated with Lower NO Bioavailability; Re-
viewed by [4]. *Alzheimers is not a CV Disorder 
Cardiovascular disorder Change in ADMA Reference 
Chronic renal failure associated  
with hypertension 
 [1,3,14,15] 
Stroke  [16,17] 
Pulmonary hypertension  [18-20] 
Left ventricular hypertrophy  [21,22] 
Type II diabetes  [23-25] 
Pre-eclampsia   [26,27] 
Heart failure   [28] 
Ischaemia  [29,30] 
Hypercholesterolemia  [31,32] 
Atherosclerosis  [33,34] 
Alzheimers*   [35,36] 
 
Table 2. Summary of Cardiovascular Disorders Where Changes in 
the Concentrations of CRP have been Measured 
Cardiovascular disorder Change in CRP Reference 
Angina  [7,9,11]; 
Myocardial infarction  [37,38] 
Atherosclerosis   [39-43] 
Diabetes  [44,45], 
Stroke  [8] 
Rheumatoid arthritis  [46-51] 
Systemic lupus erythematosus  [52-54] 
 
cholesterol levels and blood pressure identified originally in the 
Framingham study; which may further predict the risk of cardiovas-
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cular disease. The high throughput methods available to screen 
CRP levels in plasma are perhaps partly responsible for the recom-
mendation by the American Heart Association that CRP concentra-
tions should be measured routinely in patients to aid in diagnosis 
and outcome alongside the originally recommended Framingham 
criteria [12]. There have been some criticisms of this proposal as 
concentrations of CRP may range from 0.1-1000 mg/L depending 
upon the inflammatory status and this might impair the interpreta-
tion of CRP as a cardiovascular marker [13]. At present measure-
ments of ADMA are not routinely used to predict cardiovascular 
outcome, this may be partially due to the lack of accessible high 
throughput methods for screening.  
ADMA & Atherosclerosis 
 ADMA concentrations have been demonstrated to predict lu-
men occlusion [55], an important measure of atherogene sis. In 
patients with end stage renal failure, increased intima-media thick-
ness was reported to correlate with raised ADMA [33,56], and in 
isolated uterine arteries there was a correlation between raised 
ADMA and intimal hyperplasia; the latter study also suggested 
reduced ADMA metabolism by DDAH [34].  
 Regulation of circulating homocysteine is critical in maintain-
ing normal cardiovascular function with hyperhomocysteinemia 
pre-disposing towards the progression of atheroma. In hypercholes-
terolemic rabbits there are increased plasma ADMA concentrations 
[31,57] correlating with decreased ADMA metabolism and DDAH 
activity [58]. Hypercholesterolemia increases oxidative stress and 
monocyte binding to human endothelial cells [59,60], ADMA 
might have effects upon endothelial adhesion molecules. In a fur-
ther study of carotid intimal-thickness ADMA concentrations corre-
lated with increases in soluble vascular cell adhesion molecule 
(sVCAM1), which has been described as an atherosclerotic marker 
[61]. Most of the studies of ADMA and atherogenesis are associa-
tion studies and further work is needed to determine whether 
ADMA is mediating the changes observed in atherosclerosis.  
CRP & Atherosclerosis 
 High concentrations of CRP have been measured in atheroscle-
rotic plaques [41-43]. This is consistent with high levels of com-
plement 3 also seen in these plaques reviewed -[62]. In the “Rever-
sal of Atherosclerosis with Aggressive Lipid Lowering; REVER-
SAL” trial lowering cholesterol and CRP reduced the progression 
of atheroma [40,63]. CRP binds the phosphocholine of low density 
lipoprotein (LDL), increases the expression of adhesion molecules 
and promotes the uptake of LDL by macrophages [64,65].  
 A model commonly used to investigate the effects of CRP is the 
ApoE knockout mouse, which is hypercholesterolemic and devel-
ops atherosclerotic lesions [66,67], transfected with human CRP. 
Conflicting results have been generated using these mice, some 
investigators have reported activation of complement, accelerated 
atherosclerosis and increased expression of angiotensin receptor-1, 
vascular cell adhesion molecule and collagen [68]. In contrast using 
the same murine model other investigators neither reported proin-
flammatory nor proatherogenic effects [69]. 
Is there an Association between ADMA and CRP? 
 The number of studies looking at ADMA levels are a fraction 
of the number which have examined CRP. It is not surprising there-
fore that few studies have measured CRP and ADMA; Bae et al. 
found a positive correlation between ADMA and CRP plasma con-
centrations in patients with acute coronary syndrome [70] and Mal-
lamaci et al. reported a gain in the power of prediction when con-
sidering both ADMA and CRP plasma concentrations in a small 
cohort of dialysis patients [71]. 
 In studies measuring the intima-media thickness both ADMA 
and CRP concentrations correlated with the intima thickness [33]. 
These researchers proposed that there might be a relationship be-
tween these risk factors. However, in another study investigating 
carotid intima-thickness, there was no correlation between plasma 
CRP and ADMA levels [61]. There is no functional evidence pub-
lished to support a mechanistic association between these cardio-
vascular risk factors and further large scale clinical studies are re-
quired to determine if there is a true correlation between CRP and 
ADMA plasma concentrations. 
What are the Roles of ADMA? 
Formation of nitric oxide 
 Nitric oxide (NO) is an important signalling molecule. In the 
cardiovasculature it is vital in maintaining vascular tone [72] and in 
preventing leukocyte adhesion and platelet aggregation [73]. It has 
also been demonstrated to influence gene expression. NO is synthe-
sised from arginine by nitric oxide synthases (NOS) in an oxygen-
dependent reaction which utilises tetrahydrobiopterin as a cofactor 
[74,75] (Fig. 1). Limited substrate or cofactor availability leads to 
the generation of superoxide (O2
•
) from NOS which may contribute 
to endothelial dysfunction [76,77]. There are two constitutively 
expressed NOS isoforms, endothelial (eNOS; NOSIII) and neuronal 
(nNOS, NOSI), and an inducible nitric oxide synthase (iNOS; 
NOSII). All NOS isoforms were reported to be inhibited by argin-
ine analogues including L-N
G
monomethylarginine (L-NMMA; 
[78,79]). 
Modulation of Nitric Oxide by Endogenously Occurring Methy-
larginines 
 The molecules, asymmetric dimethylarginine (ADMA; N
G
 N
G
 
dimethylarginine) and L-NMMA, were identified in human urine 
[80] and later evidence suggested that levels of ADMA rose in pa-
thologies which included muscular dystrophy [81]. In 1992 Val-
lance et al. recognised that the structure of ADMA closely resem-
bled the NOS inhibitor L-NMMA [82] and ADMA was shown to 
dose-dependently attenuate the relaxation of nor-epinephrine pre-
constricted aortic rings and this was an endothelium dependent 
effect. These investigators reported that plasma concentrations of 
ADMA were significantly elevated in patients with end-stage renal 
failure and this correlated with lower levels of nitric oxide [1]. This 
was the first indication that an endogenously occurring inhibitor of 
NOS could affect cardiovascular function. Both ADMA and L-
NMMA are inhibitors of all 3 nitric oxide synthases (Fig. 1A), with 
inhibition constants in the range of 0.1-6.2 mol/L [78,79,83].  
 The reaction catalysed by NOS is complex and it has been pro-
posed that in the presence of methylarginines NOS may become 
uncoupled generating superoxide [77] (Fig. 1B). In eNOS knockout 
mice infused with ADMA, there were increased concentrations of 
superoxide and this correlated with increased staining for angio-
tensin converting enzyme [84]. In a study of dialysis patients, an 
association between ADMA concentrations and an eNOS polymor-
phism was reported [85], whether this might be an effect on NO 
production remains to be clarified. 
 Methylated arginines are taken into cells through the y+ trans-
porter and may also compete with arginine for cellular uptake [86]. 
Another endogenously occurring molecule, symmetric dimethy-
larginine (SDMA- N
G
N
G
`–dimethylarginine; structure shown in 
Fig. 1A), was found to have no effect on the production of nitric 
oxide [87], however SDMA is also transported by the y+ trans-
porter and may compete with arginine under certain circumstances. 
Formation and Metabolism of Asymmetric Dimethylarginine 
 The formation of dimethylarginines has been discussed previ-
ously [4]. Arginine residues in proteins are methylated post-
translationally in vivo by a family of enzymes called protein argin-
ine methyltransferases (PRMT: Table 3 and Fig. 2): the methyl 
group is donated by S-adenosylmethionine (SAM) with S-adenosyl- 
homocysteine (SAH) a reaction by-product [88]. Evidence from in 
vivo loading of radiolabelled methionine indicated that the methyla-
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tion of arginine residues was irreversible and that degradation of the 
methylated proteins was extremely slow [89,90].  
 Currently eight PRMT isoforms have been reported (Table 1): 
two of these can symmetrically methylate protein arginine residues 
[91-94]; five have been reported to asymmetrically methylate argin-
ine residues [95-100]; and one member of the PRMT family has no 
known ability to methylate arginine [101]. The release of free 
methylarginines has been reported to occur following hydrolysis 
and proteolysis. 
 Characterisation of the metabolism of ADMA began with ob-
servations made in rabbits that concentrations of [
14
C]labelled L-
NMMA and ADMA excreted in urine were significantly lower than 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
Fig. (1). Asymmetric dimethylarginine (ADMA) inhibits the formation of nitric oxide (NO). 
A). Nitric oxide synthases catalyse the formation of NO from arginine in the presence of NADPH, O2 and tetrahydrobiopterin (BH4). The structures of sub-
strate arginine and product citrulline are shown with the inhibitor ADMA (NGNGdimethylarginine). Inset box: structures for the endogenously occurring meth-
ylarginines L-NG-monomethylarginine (L-NMMA) and NGNG’-dimethylarginine (symmetric dimethylarginine –SDMA); L-NMMA but not SDMA inhibits 
NOS. 
B). Putative mechanism for superoxide generation in the presence of ADMA. In the presence of arginine, nitric oxide synthases produce nitric oxide and citrul-
line (i), when methylarginines are present superoxide may be generated from NOS (ii). (Flavin adenine dinucleotide (FAD); flavin monophosphate (FMN); 
calmodulin (CAM); haemoglobin (HAEM); reduced nicotinamide adenine dinucleotide phosphate (NADPH); tetrahydrobiopterin (BH4); superoxide (O2
); 
arginine (ARG). 
 
Table 3. Summary of Type 1 and Type 2 PRMT isoforms. Chromosomal Localisation, as Published by The Welcome Trust Sanger Centre 
PRMT Type Class Chromosome Arginine methylation Localisation Reference 
Type 1 PRMT1 
PRMT3 
CARM1/PRMT4 
PRMT6 
PRMT8 
PRMT2 
19q13 
11p15.1 
12p13.32 
1p13.3 
12p13.3 
21q22.3 
MMA, ADMA 
MMA, ADMA 
MMA, ADMA 
MMA, ADMA 
MMA, ADMA 
No apparent Arginine methylation 
Nucleus 
Cytosol 
Nucleus 
Nucleus 
Membrane bound 
Nucleus 
[99,100] 
[96,100]  
[102] 
[97] 
[98] 
[101] 
Type 2 PRMT5 
PRMT7 
14q11.2 
16q22.1 
MMA, SDMA 
MMA, SDMA, some ADMA 
Cytosol 
Nucleus & Cytosol 
[92,103,104] 
[93,94] 
NH2
CO2H
NH
NH2
HN
NH2
CO2H
NH
N
HN
H3C
CH3
Arginine
ADMA
BH4' NADPH, O2
NH2
CO2H
NH
NH2
O
Citrulline
Nitric oxide
+   NO
NH2
CO2H
NH
NH
HN
H3C
NH2
CO2H
NH
NH
HN
H3C
L-NMMA SDMA
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those of SDMA [105]. Dimethylarginine dimethylaminohydrolase 
(DDAH) was found to metabolise L-NMMA and ADMA to form 
methylamine or dimethylamine respectively and citrulline; DDAH 
does not metabolise SDMA. (Fig. 2; [106-107]. DDAH metabolises 
250 mol/L of the 300 mol/L generated daily, based upon urinary 
excretion of dimethylamine [108].  
 Two isoforms of DDAH have been identified [109]: human 
DDAHI was mapped to chromosome 1p22 and is more prevalent in 
the nervous system[110]. DDAHII was mapped to chromosome 
6p21.3, close to the MHC region and dot-blot analyses revealed that 
DDAHII is located in vascularised and immune tissues [110]. 
Regulation of DDAHII is altered in development [110,111], per-
haps reflecting a time when protein turnover and release of methy-
larginine is high.  
CRP an Acute Phase Inflammatory Response Protein 
 CRP was described in 1930, after a protein in plasma from pa-
tients infected with Streptococcus pneumoniae was found to pre-
cipitate in the presence of the pneumococcus cell wall protein C-
polysaccharide [112]. The gene encoding CRP has a single intron 
and has been localised to chromosome 1q21-q23 [113,114]. CRP is 
an acute phase inflammatory response protein that calcium-
dependently precipitates in the presence of phosphocholine ligand; 
which is found in membrane proteins and bacterial polysaccharides 
[115]. Mutation studies have demonstrated that the Phe66 and 
Glu81 of CRP are critical for the CRP binding to phosphocholine 
[116]. CRP also binds to the to the immunoglobulin receptors, 
FcRI and FcRII, and subsequent signalling initiates a response 
from phagocytes [117,118]. 
 Aggregated CRP or CRP complexed to ligands have been shown 
to activate complement (Fig. 3); [119-122]. CRP activation of the 
classical complement pathway initiates opsonisation and the phago-
cytosis of bacteria (for review see [123]). Aggregated CRP has been 
shown to selectively bind plasma LDL and very low density lipo-
proteins (vLDL); this has been proposed as a mechanism by which 
CRP might recognise damaged cell membranes [64]. CRP also 
binds to degraded low density lipoproteins to activate complement 
and this property of CRP might be important in atherogenesis [65]. 
 Aggregated CRP, or multivalent ligands to bound CRP, initiate 
interactions with C1q enabling activation of the classical comple-
ment pathway [120]. CRP may bind to a number of molecules in-
cluding: chromatin, histones, fibronectin, small nuclear ribonucleo-
tides, laminin and polycations. Chromatin binding to CRP has been 
suggested as a mechanism to explain how CRP might recognise and 
scavenge these proteins from damaged cells [124] (Fig. 3).  
 The anti-inflammatory effects of CRP include increasing IL-10, 
IL-1 receptor antagonist, and lowering the production of IFN and 
TNF- [123]. CRP has been reported to prevent platelet aggregation 
and this may be through the activation of platelet factors [125]. The 
extent and persistence of inflammation can be determined by fol-
lowing the plasma concentration of the acute phase CRP. The half 
life of CRP is a few hours and the CRP levels in serum reflect rapid 
changes associated with inflammation. Whether the raised concen-
trations of CRP seen in cardiovascular disorders are related to pro-
longed inflammatory responses or not is unclear, whilst myriad 
clinical studies have reported associations between CRP and car-
diovascular disorders, mechanisms to prove or disprove a causal 
role for CRP in cardiovascular pathologies are poorly characterised. 
CRP Structure 
 CRP is a pentameric protein with the five 21500 Da subunits 
arranged in a donut shape (Fig. 3) and it is a member of the pen-
taxin family [126]. The structure of CRP has been reviewed in de-
tail elsewhere [123,127]. 
 Studies have shown that the downstream effects of CRP as a 
pentamer (native CRP) are different to those of monomeric CRP 
(mCRP – modified CRP; [128]. The modified monomeric CRP is 
proinflammatory and is associated with increased release of the 
inflammatory mediators IL-8, and monocyte chemoattractant pro-
tein-1 [129,130]. The effect of mCRP on IL-8 in neutrophils might 
be coupled to the formation of peroxynitrite [129]. In addition 
mCRP has been shown to increased ICAM-1 expression in endothe-
lial cells [131]. Recently, in the ApoE knockout mouse, specific 
differences have been observed between native and modified CRP: 
with the modified CRP producing smaller plaques than native 
CRP[132]. These differences were related to the expression of ad-
hesion molecules and the authors of this study have proposed that 
some varied reports of CRP in atherogenic studies might be due to 
the differential effects of native and modified CRP [132]. 
Species Variation in CRP Levels 
 Whilst CRP is an evolutionary conserved protein, it is not an 
acute phase reactant in all mammals: in humans and rabbits CRP 
concentrations can rapidly rise from 0.1 mg/L to more than 3000-
fold following acute phase stimulation. In mice levels are hardly 
affected by inflammation reaching only 2 mg/L [133] and the Syr-
ian hamster does not have detectable levels of CRP. In rats, how-
ever, levels of CRP are constitutively high in serum (300-600 
mg/L) rising to 900 mg/L following injury [127]. CRP has also 
been described in the horseshoe crab and in other cold blooded 
invertebrates [134].  
Effects of CRP on Nitric Oxide Production 
 The use of commercially available sources of CRP without 
purification steps has been criticised [135] and focus has been 
placed upon the re-interpretation of the effects of CRP upon NO 
mediated biology. CRP was believed to attenuate NO production 
and downregulate eNOS expression [136, 137]. However, the levels 
of eNOS were not found to be altered in a murine transgenic mod-
els overexpressing CRP [68]. Clapp et al. examined the endothe-
lium specific effects of purified human CRP in vitro and in vivo and 
did not find inhibition of NO [138]. In contrast to previous reports 
these investigators found that CRP potentiated eNOS mediated 
relaxation and suggested CRP might affect the tetrahydrobiopterin 
pathway (NOS cofactor – see Fig. 1). 
 
 
 
 
 
 
Fig. (2). Formation and metabolism of ADMA. 
Arginine residues on proteins are methylated by PRMTs with S-adenosylmethionine acting as a methyl donor. Free ADMA is released as the protein under-
goes hydrolysis and proteolysis. DDAH metabolises ADMA to citrulline and dimethylamine. (Protein arginine methyltransferase (PRMT); S-
adenosylhomocysteine (SAH), S-adenosylmethionine (SAM); dimethylarginine dimethylaminohydrolase (DDAH). 
C-Reactive Protein and Asymmetric Dimethylarginine Current Pharmaceutical Design, 2007, Vol. 13, No. 00    5 
 CRP reportedly augmented the cytokine activated NO produc-
tion from iNOS [139]. However, conflicting results were observed 
in organ bath relaxation experiments using rabbit aortic rings and 
CRP from various sources, with commercial CRP alone eliciting 
vasorelaxation of the rings. The investigators controversially pro-
posed that low levels of sodium azide (NaN3), used as a preserva-
tive in commercial preparations, was responsible for reported vaso-
dilatory effects of CRP [140]. Further experiments looking at 
vasorelaxation in rat aortic vessels and mesenteric arteries deter-
mined that CRP induced relaxation was attributable to sodium azide 
and purification of CRP to remove preservatives attenuated the 
vasodilatory effects of CRP [141]. Lafuente et al. demonstrated that 
the inhibitory effect of CRP on IL-I induction of iNOS was mim-
icked by sodium azide and that purified CRP did not alter iNOS 
induction [142]. The presence of sodium azide may explain endo-
thelial activation by CRP [143]; also the decreased migration, pro-
liferation, and matrigel tube formation observed in endothelial cells 
since dialysed commercial CRP elicited no effect but vehicle buffer 
containing sodium azide had both anti-proliferative and proapop-
totic effects [144]. The presence of LPS in commercial CRP has 
been identified and some pro-inflammatory affects attributed to 
CRP may be due to this contaminant [145]. 
 Clearly the interpretation of the effects of CRP on the endothe-
lium and NO production needs to be clarified and caution should be 
taken when analysing data generated using unpurified commercial 
preparations of CRP. 
Regulation of ADMA Metabolism 
 ADMA levels are altered in many cardiovascular conditions 
and understanding the regulation of ADMA concentrations is im-
portant to understand underlying pathologies. In hypercholes-
terolemia plasma concentrations of ADMA are elevated [32]; oxi-
dation of LDL is associated with hypercholesterolemia and in an in 
vitro model oxidised LDL increased PRMT activity and decreased 
DDAH activity [58]. A cysteine residue at the active site of DDAH 
has been proposed to be oxidised by homocysteine, this mechanism 
might account for lowered DDAH activity in hypercholesterolemia 
[146]. Erythropoietin therapy to treat anaemia has been reported to 
cause hypertension in some patients; and DDAH activity has been 
demonstrated to fall, oxidation of the active site cysteine was pro-
posed to cause this effect [147]. 
 There is a correlation between insulin resistance and raised 
ADMA levels [24,148] and glucose has been shown to decrease 
DDAH and increase ADMA levels [149]. ADMA levels have fallen 
in hyperglycaemic patients treated with the diabetic drug metformin 
[150]. In addition treatment with the thiazolindinelione, rosiglita-
zone, reduced ADMA levels [151] and pioglitazone was shown to 
reduce ADMA levels by increasing DDAH activity in a rat model 
[152]. There are PPAR response elements (binding site for thia-
zolindineliones) in the DDAHII promoter [153], further studies are 
required to characterise the role of DDAH in the progression of 
Type II diabetes. 
 Blood flow may exert an affect on DDAH expression, low 
blood flow in the heart correlated with increased DDAHI expres-
sion and shear stress has been reported to alter PRMT activity [158] 
as well as activating eNOS [159]. Finally, there have been reports 
that oestrogen replacement reduced plasma concentrations of 
ADMA [160], oestrogen has been demonstrated to increase DDAH 
activity and to reduce concentrations of ADMA [155]. Reports of 
various stimuli on DDAH expression or activity have been summa-
rised in Table 4, however some of these observations have been 
made from cursory in vitro experiments and more rigorous studies 
will be needed to elucidate regulatory mechanisms of DDAH.  
Angiogenesis 
 The pro-angiogenic all-trans-Retinoic acid has been shown to 
increase DDAHII expression and lower ADMA concentrations as 
well as increasing the DDAHII promoter activity [156]. These ef-
fects are possibly mediated by a PPAR/RXR (-927) site identified 
in the DDAHII promoter [153]. DDAH overexpression increases 
tube formation in matrigel assays [161] and increases neovasculari-
sation when overexpressed in tumour cells [162]; the angiogenic 
effects of DDAH may be mediated in part by increased expression 
of VEGF [161,162]. More recently it has been shown that DDAH 
overexpression affected the hypoxia of tumours [163]. An overex-
pressing DDAH transgenic mouse has been described by Cooke et 
al. which has lower blood pressure than controls [164]. Angiogenic 
studies with these animals have supported the evidence that DDAH 
overexpression reduces ADMA concentrations and increases angi-
ogenesis [165]. 
Regulation of CRP 
 A major site of CRP synthesis is the liver and CRP is released 
from hepatocytes into the plasma; CRP is also found in lympho-
cytes, neurons and monocytes as well as in atherosclerotic plaques. 
Early studies of the CRP promoter in human hepatocytes revealed 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Cartoon summarising CRP synthesis and actions as an acute phase protein. 
CRP expression is co-operatively induced by IL-6 and IL-1ß. The pentameric CRP is transported from hepatocytes and recognises ligands, including phospho-
choline, on proteins such as chromatin or low density lipoproteins. Either protein-bound CRP or CRP aggregates activate the complement cascade culminating 
in opsonisation and phagocytosis.  
6    Current Pharmaceutical Design, 2007, Vol. 13, No. 00 Caroline L. Smith 
the presence of responsive elements to interleukin 6 (IL-6) and 
hepatocyte specific nuclear proteins [166,167]. Interleukin 6 (IL-6) 
is the major regulator of CRP but interleukin-1 (IL-1) acts in a 
co-operative manner to stimulate CRP [168]. IL-6 may be acting 
through STAT3 and C/EBPß which are in close proximity within 
the CRP promoter [169]. Variations in basal CRP levels which are 
seen in the population are proposed to arise from OCT-1 and NFB 
activation of CRP [170].  
 There is interest in the effects of currently approved therapeu-
tics to modulate CRP concentrations in cardiovascular disorders; 
statin treatments lower LDL and have also been reported to lower 
CRP levels [40,171,172] (for review see [171,173]). Anti-TNF- 
therapy (Infliximab) has been demonstrated to lower both serum 
CRP and IL-6 levels in patients with a systemic inflammatory re-
sponse [174]. Modification of the renin-angiotensin system may 
also reduce concentrations of both CRP and complement [175]. 
Measuring Levels of ADMA & CRP 
ADMA measurement 
 Several methods are available for measuring ADMA in a vari-
ety of samples and has been discussed in a previous issue of CPD 
[4]. Since this publication an ELISA has become available to meas-
ure ADMA which is able to differentiate between the asymmetri-
cally labelled and symmetrically labelled methylarginines despite 
their identical molecular weights [176]. The advantages of this high 
throughput method are immediately apparent, however, when com-
pared to HPLC, currently recognised as the gold standard for 
ADMA analysis [82], the reproducibility of the ELISA has been 
questioned [177].  
 HPLC analysis of ADMA involves pre-treatment of the samples 
using solid phase extraction followed by derivatisation with ortho-
phthaldialdehyde (OPA) reagent [178]. Alternative measurements 
of ADMA have coupled this OPA derivatisation and HPLC method 
separation to liquid mass spectrometry and reported values similar 
to other investigators (0.355 ± 0.066 M ADMA and 0.46 ± 0.092 
M for SDMA)[179]. 
CRP Measurement 
 The size of CRP has enabled the successful production of anti-
sera and immunoassays are major tools to measure CRP plasma 
concentrations. Reliable immunoassays to detect CRP were devel-
oped as early as 1978. Utilising the fluorescently labelled antibod-
ies, these assays had detection limits as low as 20 g/L [180]. High-
throughput automated radioligand binding assays utilising the 
pneumococcal C-polysaccharide have also been described with 
sensitivity as low as 1 g/L [181]. The efficient high-throughput 
methods available to accurately and sensitively measure CRP per-
haps reflect why levels have been so well characterised in disease 
states. 
Genetic Influences on the Levels of ADMA and CRP 
Polymorphisms Observed in Enzymes Regulating ADMA Levels 
 The earliest report about single nucleotide polymorphisms 
(SNP) in DDAH, identified a functional polymorphism in the 
DDAHII promoter at -871 (6G>7G) and was found in approxi-
mately 1% of the population [153]. Since this time another group 
have reported on several SNPs in DDAHI and have suggested that 
SNPs towards the 3’ end of DDAHI might be associated with pre-
eclampsia, the high blood pressure observed in the maternal vascu-
lature during pregnancy, although these were not significant with 
multiple testing criteria [182]. ADMA concentrations have previ-
ously been shown to predict the onset of pre-eclampsia [27]. Larger 
genetic epidemiological studies are needed to reveal whether these 
DDAH polymorphisms have causal effects on ADMA concentra-
tions. Although there are PRMT SNPs reported in the databases 
particularly for PRMT3(http://www.ncbi.nlm.nih.gov/SNP/), there 
are at present no reports about functional polymorphisms in PRMTs 
and it remains to be seen whether any emerge which might influ-
ence ADMA concentrations. 
Polymorphisms of CRP 
 In contrast to the limited number of studies examining the ef-
fects of polymorphisms on ADMA levels, there are numerous re-
ports detailing a correlation between CRP genotype and CRP con-
centrations. The reported CRP polymorphisms do not seem to elicit 
an effect upon the CRP amino acid sequence encoded but do affect 
CRP concentrations. Higher basal concentrations of CRP were de-
scribed in healthy adults with a +1444 C>T polymorphism in the 3’ 
UTR [183] and carriers of this +1444T polymorphism had higher 
concentrations of CRP than +1444C individuals following a moder-
ate inflammatory response [184]. In the CARDIA study, several 
CRP promoter variants were strongly associated with CRP concen-
trations and these variants were demonstrated to affect promoter-
reporter function in vitro [185]. The effects of genotype on CRP 
concentrations appear to be independent of other traditional cardio-
vascular risk factors [185]. 
 Polymorphisms in the CRP gene which increase the concentra-
tions of CRP have been suggested to predict the occurrence of arte-
rial thrombosis [186]. Functional polymorphisms of the human 
CRP gene have also shown decreased concentrations of CRP in the 
circulation and increased risk of developing systemic lupus erythe-
matosus [52-54]. The lower levels of CRP are thought to contribute 
to a decreased clearance of damaged cell membranes and to en-
hance production of autoantibodies.  
 CRP levels are influenced by IL-6 and IL-1 therefore poly-
morphisms in genes encoding for IL-6 [187] and IL-1 [188] might 
also influence the levels of CRP. There is conflicting evidence 
about TNF- polymorphisms and the effects on plasma CRP con-
centrations [187,189]. Carriers of a genetic variant in the Toll-like 
Table 4. Effects of Stimuli Able to Alter DDAH Activity. Where it has been Demonstrated that the Change was Due to a Specific DDAH Isoform, 
this has be 
Stimulus DDAH  ADMA NO Reference 
TNF-  protein / activity   [58] 
Glucose  protein / activity   [149] 
Erythropoietin  activity   [147] 
IL-1  activity   [154] 
Oestrogen  activity   [155] 
Retinoic acid  DDAHII mRNA/protein/activity   [156] 
Shear stress  DDAHI expression   [157] 
en Identified. 
C-Reactive Protein and Asymmetric Dimethylarginine Current Pharmaceutical Design, 2007, Vol. 13, No. 00    7 
receptor 4 allele (Asp299Gly), associated with an impaired inflam-
matory response, are reported to have lower CRP concentrations 
[190]. Further large scale studies are needed to determine whether 
polymorphisms of genes involved in cytokine signalling elicit sig-
nificant prolonged effects on CRP plasma concentration. 
Is ADMA a Marker for Cardiovascular Disorders or is it a Media-
tor? 
 There is now compelling data that ADMA is a biomarker for 
the progression of cardiovascular disease and there is some data 
emerging that ADMA may be functionally important. Concentra-
tions of circulating methylarginines in plasma were not thought to 
rise to levels which could affect NO synthesis in vivo. However, 
pathophysiological concentrations of ADMA were found to alter 
the expression of several genes in endothelial cells, including those 
related to bone morphogenetic proteins and PRMT3 (which is in-
volved in arginine methylation) [191] and pathway mapping of the 
microarray data suggested that ADMA alter genes involved in cell-
cycle regulation, cell proliferation, transcriptional regulation and 
metabolism [191]. In the eNOS knockout mouse, pathophysiologi-
cal concentrations of ADMA were shown to increase expression of 
angiotensin-converting enzyme and increase atherosclerotic lesion 
size [84]. There are also reports that low levels of ADMA might 
inhibit endothelial progenitor cell mobilization and differentiation 
[192].  
Is CRP a Mediator or Marker for Cardiovascular Disease? 
 Concentrations of CRP in humans escalate several 1000-fold in 
inflammation, without deleterious effects on the cardiovasculature. 
Persistently raised concentrations of CRP, above 3 mg/L, however 
have been independently linked to cardiovascular risk [7,193]. Does 
CRP contribute to the pathophysiology accompanying cardiovascu-
lar disorders or is it an acute marker of the inflammation associated 
with cardiovascular disease? 
 Complement bound to CRP has been measured in infracted 
regions of the heart [37]. In a model of ischaemic injury, human 
CRP was observed to activate complement and enhance myocardial 
damage, this effect was ameliorated by cobra venom factor, which 
disrupts complement [38]. CRP may also play a role in increasing 
vascular calcification and has been reported to correlate to the 
coronary calcification score independently of other risk factors 
[172].  
 The exact mechanisms by which CRP mediates the progression 
of cardiovascular disorders remain elusive: the long term study of 
carriers of functional CRP polymorphisms and/ or the development 
of specific CRP inhibitors are likely to be valuable tools designed to 
clarify these mechanisms.  
Potential Therapeutic Modulation of ADMA and CRP 
Targets for Altering ADMA Levels 
 Since the bioeffects of ADMA are assumed to be altering NOS 
activity and nitric oxide bioavailability, arginine supplementation 
was predicted to overcome ADMA inhibition. There have been 
mixed results using arginine supplementation to improve endothe-
lial dysfunction associated with chronic renal failure [194,195]. 
  At the present time the formation of ADMA has not been com-
prehensively characterised and therefore targeting the metabolism 
of methylarginines appears to be the better route for altering con-
centrations of ADMA. Until recently the characterisation of DDAH 
had been limited by the availability of specific inhibitors. A panel 
of new inhibitors have been described which were based upon the 
original 4124W structure described by MacAllister [196] with 
IC50s approaching 20 mol/L and no effect on NOS activity [197]. 
As a therapeutic target these inhibitors also demonstrated that 
ADMA concentrations could be raised both in vitro and in vivo 
[197]. Other potential DDAH inhibitors include chloroacetamidine 
[198] and S-nitroso-L-homocysteine [199], however, these inhibi-
tors have not yet been demonstrated to elicit a rise in ADMA con-
centrations in in vivo models. 
Targets for Altering CRP Concentrations 
 Whilst CRP concentrations are predictive of outcome for pa-
tients with myocardial infarction and angina [7,11], there is still 
disagreement about whether CRP has a causal role in pathology; 
particularly that associated with the progression of atheroma. The 
development of specific CRP inhibitors would benefit investigators 
in elucidating a role for CRP. Although there is evidence that CRP 
levels are lowered following treatment with statins [40,63,130, 
171,172] specific CRP inhibitors are needed. Potential targets might 
include CRP transport through FcRI and FcRII receptors [117, 
118]. 
CONCLUSION 
 CRP is an established marker for cardiovascular disease; how-
ever despite the numerous association studies which have character-
ised the circulating concentrations of CRP, evidence is still lacking 
which proves a mechanistic role for CRP. Further genetic-
epidemiological studies characterising functional CRP variants and 
the development of specific CRP inhibitors will help to either ac-
quit CRP as a causal agent in cardiovascular pathology or to eluci-
date its pathophysiological role.  
 ADMA concentrations are also altered in numerous cardiovas-
cular disorders but before it can reach the prominence of CRP, as a 
biomarker to diagnose cardiovascular events; more efficient screen-
ing methods are needed. The utilisation of inhibitors to disrupt 
ADMA metabolism and further studies of DDAH transgenic ani-
mals are needed to provide valuable evidence about the potential 
involvement of this pathway in the pathogenesis of cardiovascular 
complications. 
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